We evaluated the predictive factors of acute urinary morbidity (AUM) after prostate brachytherapy.
From November 2005 to January 2007, 62 patients with localized prostate cancer were treated using brachytherapy. The 125Iodine (125I) seed-delivering method was a modified peripheral pattern. The prescribed dose was 144 Gy. Urinary morbidity was scored at 3 months after implantation. The clinical and treatment parameters were analysed for correlation with AUM. In particular, in this study, Du90 (the minimal dose received by 90% of the urethra), Dup90 (the minimal dose received by 90% of the proximal half of the urethra on the bladder side) and Dud90 (the minimal dose received by 90% of the distal half of the urethra on the penile side) were analysed. We found that 43 patients (69.4%) experienced acute urinary symptoms at 3 months after implantation. Of them, 40 patients had Grade 1 AUM, one patient had Grade 2 pain, and two patients had Grade 2 urinary frequency. None of the patients had ≥Grade 3. Univariate and multivariate analysis revealed that Du90 and Dup90 were significantly correlated with AUM. In this study, Du90 and Dup90 were the most significant predictors of AUM after prostate brachytherapy.
Written by:
Ohga S, Nakamura K, Shioyama Y, Tatsugami K, Sasaki T, Nonoshita T, Yoshitake T, Asai K, Hirata H, Naito S, Honda H. Are you the author?
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan; Kyushu International Heavy Ion Beam Cancer Treatment Center, 415 Harakoga, Tosu, Saga, Japan; Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan; School of Health Sciences, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
Reference: J Radiat Res. 2014 Jul 25. pii: rru065.
doi: 10.1093/jrr/rru065
PubMed Abstract
PMID: 25062753
UroToday.com Prostate Cancer Section
